Background. Structural stigma has the potential to reduce engagement in HIV prevention and care, particularly for sexual and gender minorities (SGM) who account for the highest proportion of new HIV diagnosis in the United States. We considered if structural stigma related to sexual orientation, that is the social/cultural norms and institutional policies/practices that constrain the lives of the stigmatized, is associated with state-level HIV diagnosis and use of pre-exposure prophylaxis (PrEP).
Methods. We used a composite measure of structural stigma that was previously developed; components included proportion of same-sex couples, gay-straight alliances in public schools, policies related to discrimination of sexual orientation, and public perception toward homosexuality. Proportion of HIV diagnosis from 2008 to 2017 and PrEP use from 2012 to 2017 per 100,000 population were extracted from AIDSVu. To account for overdispersion and the hierarchical structure of our data, we used a Poisson model with robust standard errors using generalized estimating equations.
Results. States with higher (vs. lower) levels of structural stigma related to sexual orientation had lower rates of HIV diagnosis (β = −0.550; 95% CI: −0.628, −0.472) and PrEP use (β = −0.165; 95% CI: −0.203, −0.119), after adjusting for state-level covariates such as median age, percentage black race, and legislative majority party in 2013.
Conclusion. State-level stigma has been shown to reduce SGM visibility, therefore, restricting access to prevention services. These findings suggest that states with higher levels of structural stigma toward same-sex sexuality may also have lower rates of engagement in HIV prevention services.
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Comparison in AIDS-Related Mortality Between African Americans and Whites with Human Immunodeficiency Virus During the HAART Era
Jennifer Cihlar, DO 1 ; Carl Fichtenbaum, MD 2 ; 1 UC Health, Cincinnati, Ohio; 2 University of Cincinnati Medical Center, Cincinnati, Ohio Session: 148. HIV: General Epidemiology Friday, October 4, 2019: 12:15 PM Background. Higher death rates have been reported in African American (AA) compared with non-Hispanic whites with HIV infection. However, there are no published studies of attributable mortality by racial and ethnic groups. We evaluated differences in attributable mortality between AA and whites.
Methods. We conducted a retrospective review of all persons with HIV infection who received care at the University of Cincinnati Medical Center whose deaths were between 1996 and 2017. We abstracted chart data using a standard data tool and identified all deaths reported to the social security national database. Probable cause of death was assigned using the EuroSida CoDe methodology. Primary endpoint was to compare AIDS vs. non-AIDS-related deaths between AA and whites.
Results. Initial analysis of 588 deaths are reported through 2007 (44% AA and 53% white). The median age at the time of HIV diagnosis was 37 years for AA patients and 36 years for white patients, while median age at the time of death was 43 years for AA and 42 years for whites (P = ns). 16.9% of AA were women, 2.6% were transgender; 10.3% of whites were women and 1% were transgender (P < 0.02). Risk factors for HIV acquisition included: MSM, 61.3% of whites vs. 46.0% AA; heterosexual contact, 11.7% of whites vs. 13.4% for AA; and injection drug use 16.9% white vs. 18.3% AA (P < 0.0001). African Americans had both lower median CD4 counts at the time of diagnosis and within 3-6 months prior to death (167 and 68 cells/mm 3 , respectively) as compared with whites (214 and 103 cells/mm 3 , respectively) (P < 0.0001 for both). There was no statistical significance of having AIDS at entry into the practice between AA and whites (P = 0.79). AIDS-related deaths accounted for a larger percentage of overall deaths within white patients (51%) compared with AA patients (40%) (P = 0.03).
Conclusion. Our data show that while a greater percent of AIDS-related deaths were found in whites vs. AA in the early HAART era, AA patients typically have lower CD4 counts at the time of diagnosis and within 3-6 months prior to death. Future analyses will examine specific attributable mortality, HIV viremia and changes in causes of death over later HAART era. Understanding factors associated with mortality may inform care models to prevent or delay future deaths.
Disclosures. All authors: No reported disclosures. Background. Combating HIV-related disparities is a major goal of the 2020 National HIV/AIDS Strategy. However, research on HIV disparities has primarily been conducted in urban settings. A 1997-2007 study of people with HIV (PWH) at our clinic noted significantly increased mortality among high-risk non-Hispanic (NH) Black PWH (73%) compared with NH Whites (88%). This study evaluated demographic disparities in survival and disease progression in a large Midwest clinical cohort.
Contemporary Evaluation of Racial/Ethnic Disparities in Survival and Disease Progression among People with HIV in the US Midwest
Methods. We retrospectively reviewed records of 1,396 PWH receiving treatment at an HIV Clinic in Omaha, Nebraska from 2012 through 2017. We included patients over 19 years old with diagnosed HIV, a minimum of two visits, and no lapse in care >2 years. Patients were stratified into low-risk (CD4 >100 cells/mm 3 and HIV viral load <250,000 copies/mL) and high-risk (all others) groups. Cox proportional hazard models and Kaplan-Meier curves with log-rank tests compared patient demographics and mortality. Generalized estimating equations modeled change in CD4 count over time.
Results. No significant difference in mortality was noted across race/ethnicity categories (P = 0.286). Several clinical and demographic characteristics, including CD4 counts <500 cells/mm 3 , were significantly associated with increased mortality ( Figure  1) . Compared with NH Whites, mean CD4 counts ( Figure 2 ) were significantly lower for NH Blacks (P = 0.001), Hispanics (P = 0.006), and Others (P = 0.013). High-risk status was associated with mortality (P < 0.001), but no significant differences in mortality were noted across race/ethnicity categories after stratifying for patient risk status (Figures 3 and 4) .
Conclusion. Significant racial/ethnic disparities in HIV disease progression among PWH at a Midwest HIV Clinic persist. However, in contrast to the 1997-2007 study, disparities in survival were not observed among high-risk PWH. As our patient demographics are essentially the same, the reduction of this disparity suggests needed investigation of whether these changes are the result of better antiretroviral efficacy or if social determinants of health in the region have improved. Systems-level interventions are needed to ensure all PWH benefit from continuing advances in HIV research and care.
